Skip to main content
OpenTrials
Completed

NCT Number: NCT06633757

Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance

This is a multi-dose study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The primary objective of this study is to determine the impact of multiple doses of inhaled RCT1100, administered via nebulizer, on MCC with adult participants with Primary Ciliary Dyskinesia caused by pathogenic mutations in the DNAI1 Gene.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Major Inclusion Criteria:

  • The participant is a male or female, 18 to 75 years of age, inclusive, at the time of consent.
  • Participant has disease-causing (pathogenic and/or likely pathogenic) mutations in the DNAI1 gene.
  • The participant has a percent predicted forced expiratory volume in 1 second (FEV1pp) of at least 40% predicted.

Exclusion criteria

  • History or presence of clinically significant medical, surgical, clinical laboratory, or psychiatric condition or disease.
  • History of cancer, with exception of adequately treated basal cell or squamous cell carcinoma of the skin.
  • Predisposition to bleeding or clinically meaningful hemorrhagic event in the 12 months prior
  • Medically significant hemoptysis.
  • Anticoagulation therapy for the treatment of a pulmonary embolus or has had a pulmonary embolus in the last 6 months of screening.
  • Active tuberculosis infection.
  • 12-lead ECG with QT interval >450 msec (or >480 msec for BBB)
  • Laboratory abnormalities in clinical laboratory tests at screening:
  • Serum creatinine level
  • Total bilirubin, aspartate aminotransferase or alanine aminotransferase values
  • Hematological or coagulation values outside the normal reference range
  • Any medical history of disease that has the potential to cause a rise in total bilirubin over the ULN.
  • COVID-19 infection within 4 weeks of Screening or receipt of COVID-19 vaccine within 2 weeks prior to first dose of RCT1100.
  • Receipt of vaccine with live virus, attenuated live virus, or live viral components within 2 weeks prior to first dose of RCT1100 or to receive these vaccines during treatment or within 8 weeks of completion of study treatment.

Other protocol defined inclusion/exclusion criteria may apply.

Treatment and study plan

RCT1100

Drug

mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer

Primary outcomes

  1. To Determine the impact of multiple doses of RCT1100 on MCC

    Time frame: Baseline through Week 12

    The Change in Mucociliary and Cough Clearance through 1 hour after radiotracer administration by either the albumin-based PRMC or sulfur-colloid technique

Sponsors and collaborators

Lead sponsor

ReCode Therapeutics

Industry

Registry information

Official study title

A Phase 1b, Open-label, Study of RCT1100 in Adults With Primary Ciliary Dyskinesia Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance and Other Measures of Pharmacodynamic Activity

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Oct 9, 2024
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.